课题基金 / 基金详情

University of Rochester Clinical Site within the NEXT Network of Clinical Trials

University of Rochester Clinical Site within the NEXT Network of Clinical Trials
NEXT 临床试验网络内的罗切斯特大学临床站点
批准号:
10743143
负责人:
ROBERT G. HOLLOWAY
金额:
$42.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-07-01 至 2028-06-30

项目摘要

项目成果

ROBERT G. HOLLOWAY的其他基金

相似基金

相关文献

中文摘要
翻译
罗切斯特大学医学中心及其神经科学研究人员为神经系统疾病的实验疗法提供了40多年的领导和有意义的贡献。自2011年神经科学临床试验卓越网络(NeuroNEXT)成立以来,罗切斯特大学网站(UR-NEXT)参与了11项资助研究中的9项,表现出比前两个获奖期更好的表现,并通过在整个网络中分享我们的专业知识,为其成功做出了贡献。UR-Next网站处于独特的地位,可以为罕见疾病的研究和基因和基因靶向治疗试验的实施做出贡献,并培训早期调查人员成为该领域的领导者。我们有51名潜在的合作研究人员,其中包括25名罕见疾病研究或基因疗法临床试验方面的专家,以及17名在我们的NINDS T32博士后培训项目-神经疾病实验疗法培训项目中担任导师的专家,该项目目前处于持续资助的第32个年头。这些研究人员中的许多人领导着罕见疾病临床试验的准备工作,并使研究计划能够在地区、国家和国际范围内开展。UR-NEXT将继续提高其作为针对成人和儿童神经疾病进行高效、公平和高度完整的NeuroNEXT临床试验的模范临床试验网站的表现,并通过以下方式增强我们的资格和成就:1)扩大我们在实验治疗方面具有特殊专业知识的杰出合作研究人员队伍,并促进他们对NeuroNEXT和基因治疗联盟的成功贡献;2)领导社区和多方利益相关者的全面参与,包括与值得信赖的社区成员建立可信的关系,以定制和改进我们的招募和保留方法以及临床试验中的多样性;3)通过部署“Study Start-up Bundles”这一社区知情的招募和保留活动问卷,并为每个NeuroNEXT临床试验执行研究后招聘策略分析,加强我们的绩效改进方法;4)将早期研究人员纳入我们的实验治疗培训计划中的职业发展和培训机会,以确保他们成功过渡到NIH/NINDS赞助的职业发展奖;以及5)在罕见疾病研究、基因治疗试验和数字工具的结合方面提供领导,同时在NeuroNEXT、NINDS和其他领域协作和传播我们的成功。UR-NEXT将由兼容并蓄、严谨的研究人员、团队合作伙伴、跨界人员、流程创新者、熟练的沟通者和系统思考者组成,以公平地改善翻译过程和受神经疾病影响的儿童、成人和家庭的生活。
英文摘要
The University of Rochester Medical Center and its neuroscience investigators have provided over four decades of leadership and meaningful contributions to experimental therapeutics for neurological disease. Since the inception of the Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) in 2011, the University of Rochester site (UR-NEXT) has contributed to its success by participating in 9 of 11 funded studies, by showing improved performance over the two prior award periods, and by sharing our expertise throughout the Network. The UR-NEXT site is uniquely positioned to contribute to rare disease research and the implementation of gene and gene-targeted therapy trials, and to train early-stage investigators to be leaders in the field. We have 51 potential co-investigators, including 25 experts in rare disease research or gene-therapy clinical trials, and 17 who are mentors within our NINDS T32 post-doctoral training program, Experimental Therapeutics of Neurological Disease, now in its 32nd year of continuous funding. Many of these investigators lead rare disease clinical trial readiness and enabling research programs with regional, national, and international reach. UR-NEXT will continue to improve its performance as an exemplary clinical trial site that conducts efficient, equitable, and high-integrity NeuroNEXT clinical trials for adult and child neurological diseases, and bolster our qualifications and achievement by: 1) expanding our cadre of exceptional co-investigators with special expertise in experimental therapeutics and to foster their successful contributions to NeuroNEXT and the Gene Therapy Consortium; 2) leading a comprehensive effort of community and multistakeholder engagement, including building authentic relationships with trusted community members, to customize and improve our approach to recruitment and retention, and the diversity in our clinical trials; 3) strengthening our approach to performance improvement by deploying “Study Start-Up Bundles”, a Community-Informed Recruitment and Retention Activity Questionnaire, and by performing a post-study Recruitment Strategy Analysis for each NeuroNEXT clinical trial; 4) integrating early-stage investigators into the career development and training opportunities within our experimental therapeutics training program to ensure their successful transition to an NIH/NINDS-sponsored career development award; and 5) providing leadership in rare disease research, gene therapy trials, and the incorporation of digital tools while collaborating and disseminating our successes across NeuroNEXT, NINDS, and beyond. UR-NEXT will be inclusive, rigorous researchers, team players, boundary crossers, process innovators, skilled communicators, and system thinkers to equitably improve the translational process and the lives of children, adults, and families affected by neurological disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome: The TopCSPN Randomized Clinical Trial.
托吡酯对伴有代谢综合征的隐源性感觉周围神经病患者的安全性和有效性:TopCSPN 随机临床试验。
DOI: 10.1001/jamaneurol.2023.3711
发表时间: 2023
期刊: JAMA neurology
影响因子: 29
作者: [Smith,AGordon, Singleton,JRobinson, Aperghis,Adrienne, Coffey,ChristopherS, Creigh,Peter, Cudkowicz,Merit, Conwit,Robin, Ecklund,Dixie, Fedler,JanelK, Gudjonsdottir,Anna, Hauer,Peter, Herrmann,DavidN, Kearney,Marianne, Kissel,John, Klin]
通讯作者: Klin
University of Rochester Clinical Site within the NEXT Network of Clinical Trials
  • 批准号:
    10189726
  • 项目类别:
  • 资助金额:
    $30.57万
  • 财政年份:
    2018
  • 负责人:
    ROBERT G. HOLLOWAY
  • 依托单位:
Research Project 2 will use remote assessments to engage large, novel populations of participants with Parkinson disease
  • 批准号:
    10017342
  • 项目类别:
  • 资助金额:
    $21.02万
  • 财政年份:
    2018
  • 负责人:
    ROBERT G. HOLLOWAY
  • 依托单位:
University of Rochester Clinical Site within the NEXT Network of Clinical Trials
  • 批准号:
    9975927
  • 项目类别:
  • 资助金额:
    $30.57万
  • 财政年份:
    2018
  • 负责人:
    ROBERT G. HOLLOWAY
  • 依托单位:
Research Project 2 will use remote assessments to engage large, novel populations of participants with Parkinson disease
  • 批准号:
    10242057
  • 项目类别:
  • 资助金额:
    $22.14万
  • 财政年份:
    2018
  • 负责人:
    ROBERT G. HOLLOWAY
  • 依托单位:
海外基金